Coccidioidin, an extract from the saprophytic mycelial form of Coccidioides spp., has been a very useful antigen preparation both for skin and serological tests for coccidioidomycosis. Unfortunately, coccidioidin is not currently available for skin testing in the United States. Coccidioidin has been produced commercially in Mexico by a vaccine and reagents laboratory of the Mexican Federal Government. It also has been produced at the Microbiology Laboratory of the Faculty of Medicine, Universidad Nacional Autónoma de México exclusively as an antigen for research projects. The objective of the study was to compare both coccidioidins in their reactivity and safety when applied in humans. One hundred and eighty-four volunteers were tested; median age was 33 (range 14-82). When the cutoff point is set in 5 mm, 88 subjects (47.8%) had a positive test for the commercial coccidioidin and 76 (41.3%; CI(95%) 0.50, 1.15; P = 0.20) were positive with the research antigen. Seventy-five subjects were positive for both antigens and 96 were negative for both. Fifty-nine subjects (31.3%) reported an adverse reaction after the application of the antigen; they were mostly very mild local reactions. Mexican research coccidioidin is a safe and reliable antigen that can be used for the detection of coccidioidomycosis infection in mammals.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11046-010-9280-y | DOI Listing |
Am J Trop Med Hyg
April 2019
Department of Microbiology, School of Medicine, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Mexico.
Med Mycol
July 2020
Division of Infectious Diseases, Mayo Clinic Hospital, Phoenix, Arizona.
Coccidioidomycosis is an endemic fungal infection of the desert southwestern United States. Intact cellular immunity is critical to the control of this infection. A recently released reformulated spherulin antigen (Spherusol; Nielsen BioSciences, Inc.
View Article and Find Full Text PDFMycopathologia
August 2019
Southern Arizona Veterans Affairs Health Care System, 3601 S. Sixth Avenue, Tucson, AZ, 85745, USA.
Background: A reformulated skin test for coccidioidomycosis, Spherusol, was recently approved for use in the USA. We hypothesized that it could be useful in predicting severity of illness and outcome in various types of coccidioidomycosis.
Methods: Subjects with non-meningeal coccidioidomycosis attending a clinic in the coccidioidal endemic region were skin tested with Spherusol and clinical data were collected at the time of testing and at follow-up.
Rev Alerg Mex
December 2019
Instituto Mexicano del Seguro Social, Hospital de Especialidades 25, Unidad Médica de Alta Especialidad, Nuevo León, México.
Background: Dialyzable leukocyte extracts (DLE) have been used to treat several cellular immunodeficiency.
Objective: To review the experience of a tertiary hospital in the use of DLE for the treatment of recurrent or severe infections in children with acquired cellular immunodeficiency not due to HIV.
Methods: We reviewed the medical records of all children who received treatment with EDL of human or bovine origin between 1986 and 2000 to detect recurrent or severe infections without response to a specific antimicrobial therapy and with a quantitative or qualitative deficit in the cellular immune response.
Rev Iberoam Micol
September 2018
Unidad Micología, Hospital de Infecciosas F. J. Muñiz, Ciudad Autónoma de Buenos Aires, Argentina.
The case of a 60 year old woman with hemoptysis and a thin-walled cavitary lesion at the upper lobe of the right lung is presented. The woman presented at the Mycology Unit of the Muñiz Hospital in Buenos Aires City 3 months after the beginning of her clinical manifestations. A hyaline micelial fungus with chlamido-arthroconidias was isolated from the bronchoalveolar lavage.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!